Literature DB >> 18063425

Using evolutionary tools to refine the new hypervariable region 3 within the envelope 2 protein of hepatitis C virus.

Manuela Torres-Puente1, José M Cuevas, Nuria Jiménez-Hernández, María Alma Bracho, Inmaculada García-Robles, Borys Wrobel, Fernando Carnicer, Juan del Olmo, Enrique Ortega, Andrés Moya, Fernando González-Candelas.   

Abstract

The envelope 2 protein of hepatitis C virus (HCV) presents three hypervariable regions, named HVR1, HVR2 and HVR3, in which the presence of antigenic sites has been described. Genetic variability in these regions may reflect the generation of escape mutants as a consequence of the immune response. Therefore, these regions would tend to accumulate amino acid changes along the infection process, an effect that could be accelerated by antiviral treatments. In this study, we have analyzed the E1-E2 region of 23 HCV patients non-responders to antiviral treatment, 7 of which were infected with subtype 1a, 15 with subtype 1b, and 1 with a new HCV-1 subtype, before and after 6 and/or 12 months of peg-interferon+ribavirin treatment. We have sequenced about 100 clones from each sample, analyzing a total of 4906 sequences. A detailed analysis of the evolutionary forces acting along the genome region studied confirmed the existence of the three hypervariable regions, characterized by significant changes in amino acid composition between samples taken at different times from the same patient and a high number of sites evolving under positive selection. Moreover, for the recently described HVR3, our results suggest that its location could be restricted to residues 434-450, instead of the originally postulated 431-466.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18063425     DOI: 10.1016/j.meegid.2007.10.005

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  8 in total

1.  Phylogeography and molecular evolution of potato virus Y.

Authors:  José M Cuevas; Agnès Delaunay; Johan C Visser; Dirk U Bellstedt; Emmanuel Jacquot; Santiago F Elena
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

2.  Patient-to-patient transmission of hepatitis C virus (HCV) during colonoscopy diagnosis.

Authors:  Fernando González-Candelas; Silvia Guiral; Rosa Carbó; Ana Valero; Hermelinda Vanaclocha; Francisco González; Maria Alma Bracho
Journal:  Virol J       Date:  2010-09-08       Impact factor: 4.099

3.  Structural basis for broad neutralization of hepatitis C virus quasispecies.

Authors:  Pascal Lapierre; Myriam Troesch; Fernando Alvarez; Hugo Soudeyns
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

4.  A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data.

Authors:  Alicia Amadoz; Fernando González-Candelas
Journal:  Evol Bioinform Online       Date:  2015-02-23       Impact factor: 1.625

5.  New insight into HCV E1/E2 region of genotype 4a.

Authors:  Nehal Hussein; Abdel-Rahman N Zekri; Mohamed Abouelhoda; Hanaa M Alam El-Din; Ahmed Abdelwahab Ghamry; Mahmoud A Amer; Ghada M Sherif; Abeer A Bahnassy
Journal:  Virol J       Date:  2014-12-30       Impact factor: 4.099

Review 6.  Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay?

Authors:  Daniele Lapa; Anna Rosa Garbuglia; Maria Rosaria Capobianchi; Paola Del Porto
Journal:  Cells       Date:  2019-04-03       Impact factor: 6.600

7.  Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin.

Authors:  José Manuel Cuevas; Manuela Torres-Puente; Nuria Jiménez-Hernández; María Alma Bracho; Inmaculada García-Robles; Boris Wrobel; Fernando Carnicer; Juan del Olmo; Enrique Ortega; Andrés Moya; Fernando González-Candelas
Journal:  PLoS One       Date:  2008-08-26       Impact factor: 3.240

Review 8.  Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies.

Authors:  Heidi E Drummer
Journal:  Front Microbiol       Date:  2014-07-03       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.